Business Description
Merus NV
ISIN : NL0011606264
Description
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 29.14 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 14.65 | |||||
| Beneish M-Score | -2.56 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -5.9 | |||||
| 3-Year EBITDA Growth Rate | -5.5 | |||||
| 3-Year EPS without NRI Growth Rate | -2.2 | |||||
| 3-Year FCF Growth Rate | -0.7 | |||||
| 3-Year Book Growth Rate | 23.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 39.4 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 85.83 | |||||
| 9-Day RSI | 75.19 | |||||
| 14-Day RSI | 67.41 | |||||
| 6-1 Month Momentum % | 99.02 | |||||
| 12-1 Month Momentum % | 141.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.34 | |||||
| Quick Ratio | 5.34 | |||||
| Cash Ratio | 5.13 | |||||
| Days Sales Outstanding | 29.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.3 | |||||
| Shareholder Yield % | -0.06 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -356.22 | |||||
| Net Margin % | -352.56 | |||||
| FCF Margin % | -332.12 | |||||
| ROE % | -52.64 | |||||
| ROA % | -38.23 | |||||
| ROIC % | -148.16 | |||||
| ROC (Joel Greenblatt) % | -638.74 | |||||
| ROCE % | -46.78 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 55.71 | |||||
| PB Ratio | 7.85 | |||||
| Price-to-Tangible-Book | 8 | |||||
| EV-to-EBIT | -15.54 | |||||
| EV-to-EBITDA | -15.81 | |||||
| EV-to-Revenue | 55.38 | |||||
| EV-to-Forward-Revenue | 62.28 | |||||
| EV-to-FCF | -17.07 | |||||
| Price-to-Net-Current-Asset-Value | 10.52 | |||||
| Price-to-Net-Cash | 11.13 | |||||
| Earnings Yield (Greenblatt) % | -6.43 | |||||
| FCF Yield % | -5.27 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers